Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer

Nicholas Zaorsky, Robert B. Den, Laura A. Doyle, Adam P. Dicker, Mark D. Hurwitz

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

External beam radiation therapy (EBRT) combined with brachytherapy (BT) is an attractive treatment option for select patients with clinically localized prostate cancer. Either low- or high-dose rate BT may be combined with EBRT ('LDR-BT boost,' 'HDR-BT boost,' respectively). HDR-BT boost has potential theoretical benefits over LDR-BT boost or external beam radiation therapy monotherapy in terms of radiobiology, radiophysics and patient convenience. Based on prospective studies in this review, freedom from biochemical failure (FFBF) rates at 5 years for low-, intermediate- and high-risk patients have generally been 85-100%, 68-97%, 63-85%, respectively; late Radiotherapy and Oncology Group Grades 3 and 4 genitourinary and gastrointestinal toxicities are seen in <8% of patients. HDR-BT boost is now a relatively well-established treatment modality for certain intermediate-risk and high-risk prostate cancer patients, though limitations exist in drawing conclusions from the currently published studies.

Original languageEnglish (US)
Pages (from-to)751-763
Number of pages13
JournalExpert Review of Medical Devices
Volume10
Issue number6
DOIs
StatePublished - Nov 1 2013

All Science Journal Classification (ASJC) codes

  • Surgery
  • Biomedical Engineering

Fingerprint Dive into the research topics of 'Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this